Ahead of print

Case report

Progressive Keratoconus as a Complication of Atopic Keratoconjunctivitis: A Case Report

Full Text links

Summary

Purpose: Presentation of a case report demonstrating the complexity of care for a patient with atopic keratoconjunctivitis (AKC), including the management of complications such as corneal ulceration, development of keratoconus, corticosteroid-induced intraocular pressure elevation, and cataract formation.

Material and Methods: We describe a case of a 52-year-old male with a marginal corneal ulcer within the context of atopic blepharokeratoconjunctivitis, focusing on complications and the need for intensive local and systemic therapy to stabilize the disease.

Results: Intensive therapy led to a gradual improvement of the disease. Corneal cross-linking stabilized keratoconus, intraocular pressure elevation was successfully managed with anti-glaucoma medication, and cataract surgery resulted in a significant improvement of visual function.

Conclusion: This case report highlights the importance of early diagnosis and the need for long-term, multidisciplinary care in patients with AKC. Regular follow-up examinations, patient education, and a combination of local, systemic, and surgical therapy are essential in order to prevent complications and stabilize the disease.

References

  1. Azari AA, Arabi A. Conjunctivitis: A Systematic Review. J Ophthalmic Vis Res. 2020 Aug 6;15(3):372-395. doi: 10.18502/jovr.v15i3.7456
  2. Chen JJ, Applebaum DS, Sun GS, Pflugfelder SC. Atopic keratoconjunctivitis: A review. J Am Acad Dermatol. 2014 Mar;70(3):569-575. Epub 2013 Dec 15. doi: 10.1016/j.jaad.2013.10.036
  3. Bielory B, Bielory L. Atopic dermatitis and keratoconjunctivitis. Immunol Allergy Clin North Am. 2010 Aug;30(3):323-336. doi: 10.1016/j.iac.2010.06.004
  4. Gordon-Shaag A, Millodot M, Shneor E. The Epidemiology and Etiology of Keratoconus. Int J Keratoco Ectatic Corneal Dis. 2012;1(1):7- 15.
  5. Hossain IT, Sanghi P, Manzouri B. Pharmacotherapeutic management of atopic keratoconjunctivitis. Expert Opin Pharmacother. 2020 Oct;21(14):1761-1769. Epub 2020 Jun 30 doi: 10.1080/14656566.2020
  6. Erdinest N, Noyman DBE, London N, et al. Applications of topical immunomodulators enhance clinical signs of vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis (AKC): a meta-analysis. Int Ophthalmol. 2024 Mar 24;44(1):157. doi: 10.1007/s10792-024-03097-7
  7. Gaballa SA, Kompella UB, Elgarhy O, et al. Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives. Drug Deliv Transl Res. 2021 Jun;11(3):866-893. doi: 10.1007/s13346-020-00843-z
  8. Weng SF, Jan RL, Wang JJ, Tseng SH, Chang YS. Association between atopic keratoconjunctivitis and the risk of keratoconus. Acta Ophthalmol. 2021 Feb;99(1):e54-e61. Epub 2020 Jun 22. doi: 10.1111/aos.14509
  9. Jan RL, Weng SF, Wang JJ, Tseng SH, Chang YS. Association between atopic keratoconjunctivitis and the risk of corneal ulcer. Br J Ophthalmol. 2021 Dec;105(12):1632-1637. Epub 2020 Oct 3. doi: 10.1136/bjophthalmol-2020-316206
  10. Fujishima H, Okada N, Dogru M, et al. The role of Staphylococcal enterotoxin in atopic keratoconjunctivitis and corneal ulceration. Allergy. 2012 Jun;67(6):799-803. Epub 2012 Apr 10doi: 10.1111/j.1398-9995.2012.02818.x
  11. Veliká V, Rozsíval P, Jirásková N, Raiskup F. Treatment of keratoconus by accelerated cross-linking. Cesk Slov Oftalmol. 2017;73(4):134- 139.
  12. Benáková N. Ekzémy očních víček a screening očního postižení u atopické dermatitidy. Česko‑slovenská dermatol. 2023;98(6):288- 294.
  13. Achten R, Thijs J, van der Wal M, et al. Ocular surface disease in moderate-to-severe atopic dermatitis patients and the effect of biological therapy. Clin Exp Allergy. 2024 Apr;54(4):241-252. Epub 2024 Feb 8. doi: 10.1111/cea.14461
  14. Gkalpakiotis S, Tánczosová M, Skalická P. Oční komorbidity u atopické dermatitidy a kazuistika pacienta se závažnými očními komplikacemi léčeného dupilumabem. Remedia. 2020; 30:361-364.
  15. Stingeni L, Ferrucci S, Amerio P, Foti C, Patruno C, Girolomoni G. Lebrikizumab: a new anti-IL-13 agent for treating moderate-to-severe atopic dermatitis. Expert Opin Biol Ther. 2025 Jan;25(1):15-20. Epub 2024 Dec 6. doi: 10.1080/14712598.2024.2435427
  16. Starr CE, Nichols KK, Lang JR, Brady TC. The Phase 3 INVIGORATE Trial of Reproxalap in Patients with Seasonal Allergic Conjunctivitis. Clin Ophthalmol. 2023 Dec 13;17:3867-3875. doi: 10.2147/OPTH.S441009